Abstract
DTaP and Tdap vaccines have been utilized for prevention of diphtheria, tetanus, and pertussis in the United States since 1996 and 2005, respectively. However, the protective immunity that these vaccines provide is not long-term, and the disease is re-emerging. DTaP and Tdap are administered by intramuscular injection to induce systemic humoral immunity. In this study, Wolf et al. (e00607-20) investigate mucosal immunization through intranasal administration. A murine model was used to study short- and long-term protection elicited after intranasal vaccination. Nasal immunization provided long-term protection, especially when whole beta-glucan and alum adjuvants were used to induce local and systemic humoral immune responses persisting out to 6 months postboost immunization.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
